These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21001709)

  • 1. Observations on fibrinolysis; plasminogen, plasmin, and antiplasmin content of human blood.
    MACFARLANE RG; PILLING J
    Lancet; 1946 Oct; 2(6425):562-5. PubMed ID: 21001709
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
    Silence K; Collen D; Lijnen HR
    Blood; 1993 Aug; 82(4):1175-83. PubMed ID: 7688990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
    Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
    Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
    Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
    Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 9. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen-plasmin system. VII. Potentiation of antifibrinolytic action of a synthetic inhibitor, tranexamic acid, by alpha 2-macroglobulin antiplasmin.
    Abiko Y; Iwamoto M
    Biochim Biophys Acta; 1970 Sep; 214(3):411-8. PubMed ID: 4251764
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
    Sakai M; Watanuki M; Matsuo O
    Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ENHANCEMENT OF FIBRINOLYSIS AND ANTAGONISM OF ANTIPLASMIN BY REVERSIBLE PLASMIN INHIBITORS.
    MAXWELL RE; LEWANDOWSKI V; NICKEL VS
    Life Sci (1962); 1965 Jan; 4():45-51. PubMed ID: 14257064
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular markers of hemostatic-mechanisms--plasmin-alpha 2 plasmin inhibitor complex].
    Kawai Y; Watanabe K
    Rinsho Byori; 1989 Mar; 37(3):248-55. PubMed ID: 2526263
    [No Abstract]   [Full Text] [Related]  

  • 15. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
    Holvoet P; de Boer A; Verstreken M; Collen D
    Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbon monoxide and nitric oxide modulate α₂-antiplasmin and plasmin activity: role of heme.
    Arkebauer MR; Kanaparthy SS; Malayaman SN; Vosseller K; Nielsen VG
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):712-9. PubMed ID: 22024794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
    Bønløkke ST; Fenger-Eriksen C; Ommen HB; Hvas AM
    Blood Adv; 2023 Nov; 7(22):7056-7066. PubMed ID: 37756519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathophysiological role of fibrinolysis inhibitors.
    Lijnen HR; Collen D
    Ric Clin Lab; 1984; 14(3):499-505. PubMed ID: 6084295
    [No Abstract]   [Full Text] [Related]  

  • 19. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The initiation of fibrinolysis in alpha 2-plasmin inhibitor deficient plasma. Role of fibrin.
    Ichinose A; Aoki N
    Thromb Res; 1986 Mar; 41(6):847-54. PubMed ID: 2939589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.